keyword
MENU ▼
Read by QxMD icon Read
search

Medullary thyroid carcinoma

keyword
https://www.readbyqxmd.com/read/28729773/is-new-american-thyroid-association-risk-classification-for-hereditary-medullary-thyroid-carcinoma-applicable-to-chinese-patients-a-single-center-study
#1
Xiwei Zhang, Dangui Yan, Junyi Wang, Hanfeng Wan, Yongxia Zhang, Yabing Zhang, Yuqin He, Wensheng Liu, Bin Zhang
OBJECTIVE: The American Thyroid Association (ATA) proposed a new risk classification for hereditary medullary thyroid carcinoma (MTC) in 2015. This study aimed to assess whether the new guidelines are suitable for the Chinese population, and reported our experience on prophylactic thyroidectomy. METHODS: A total of 73 patients from 22 families were screened as rearranged during transfection (RET) mutation carriers from 2010 to 2016 in Cancer Hospital, Chinese Academy of Medical Science; the medical history for each patient was collected...
June 2017: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/28710706/synchronous-and-metastatic-papillary-and-follicular-thyroid-carcinomas-with-unique-molecular-signatures
#2
Vincent Cracolici, Ibro Mujacic, Sabah Kadri, Mir Alikhan, Nifang Niu, Jeremy P Segal, Lauren E Rosen, David H Sarne, Adam Morgan, Samy Desouky, Nicole A Cipriani
Despite the relatively high prevalence of thyroid cancer, the occurrence of multiple synchronous, distinct subtypes of primary thyroid carcinoma is uncommon. The incidental finding of papillary thyroid microcarcinoma in a gland with a biologically relevant follicular or medullary carcinoma is more frequent than the synchronous occurrence of multiple clinically significant carcinomas. We report a case of synchronous papillary and follicular thyroid carcinomas metastatic to lymph node and bone, respectively. Next generation sequencing showed BRAF V600E mutation in the primary papillary carcinoma and NRAS Q61R mutation in the primary follicular carcinoma and bony metastasis...
July 14, 2017: Endocrine Pathology
https://www.readbyqxmd.com/read/28698976/medullary-thyroid-cancer-clinical-characteristics-and-new-insights-into-therapeutic-strategies-targeting-tyrosine-kinases
#3
REVIEW
Sadegh Rajabi, Mehdi Hedayati
Medullary thyroid carcinoma (MTC) is a hyperplasia of thyroid C-cells, accounting for 5-10% of all thyroid cancers. MTCs may appear as sporadic or hereditary forms, and several molecules and signaling pathways have been found to function defectively in MTC cells. Tyrosine kinases are the most well-studied molecules that have abnormal function in these tumor cells. Due to their limited response, chemotherapeutic agents and radiation therapy are not effective in treating patients with advanced metastatic MTC...
July 11, 2017: Molecular Diagnosis & Therapy
https://www.readbyqxmd.com/read/28698189/a-comprehensive-review-on-men-2b
#4
Frederic Castinetti, Jeff Moley, Lois M Mulligan, Steven G Waguespack
MEN2B is a very rare autosomal dominant hereditary tumor syndrome associated with medullary thyroid carcinoma (MTC) in 100% cases, pheochromocytoma in 50% cases, and multiple extra-endocrine features, many of which can be quite disabling. Only few data are available in the literature. The aim of this review is to try to give further insights into the natural history of the disease and to point out the missing evidence that would help clinicians optimize the management of such patients. MEN2B is mainly characterized by the early occurrence of MTC, which led the American Thyroid Association to recommend preventive thyroidectomy before the age of 1...
July 11, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28687633/united-states-and-european-multicenter-prospective-study-for-the-analytical-performance-and-clinical-validation-of-a-novel-sensitive-fully-automated-immunoassay-for-calcitonin
#5
George J Kahaly, Alicia Algeciras-Schimnich, Thomas E Davis, Tanja Diana, Joachim Feldkamp, Stefan Karger, Jochem König, Mark A Lupo, Friedhelm Raue, Matthew D Ringel, Jennifer A Sipos, Juergen Kratzsch
BACKGROUND: The objective of this study is the validation and proof of clinical relevance of a novel electrochemiluminescence immunoassay (ECLIA) for the determination of serum calcitonin (CT) in patients with medullary thyroid carcinoma (MTC) and in different diseases of the thyroid and of calcium homeostasis. METHODS: This was a multicenter prospective study on basal serum CT concentrations performed in 9 US and European referral institutions. In addition, stimulated CT concentrations were measured in 50 healthy volunteers after intravenous calcium administration (2...
July 7, 2017: Clinical Chemistry
https://www.readbyqxmd.com/read/28683235/prognostic-variables-affecting-primary-treatment-outcome-for-medullary-thyroid-cancer
#6
Suhael Momin, Deborah Chute, Brian Burkey, Joseph Scharpf
OBJECTIVE: Identifying prognostic risk factors and determining the efficacy of common surgical treatments is critical to determine optimal treatment strategies for patients with medullary thyroid carcinoma (MTC). The objective of this study was to review a contemporary institutional experience with medullary thyroid carcinoma primary treatment with two goals: to identify prognostic factors that affect survival and to study the effect of neck dissection on those outcomes. METHODS: This study is a retrospective case series of patients with MTC who underwent at least a total thyroidectomy with curative intent...
July 6, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28676824/prognostic-impact-of-mir-224-and-ras-mutations-in-medullary-thyroid-carcinoma
#7
Elisabetta Cavedon, Susi Barollo, Loris Bertazza, Gianmaria Pennelli, Francesca Galuppini, Sara Watutantrige-Fernando, Simona Censi, Maurizio Iacobone, Clara Benna, Federica Vianello, Stefania Zovato, Davide Nacamulli, Caterina Mian
Little is known about the function of microRNA-224 (miR-224) in medullary thyroid cancer (MTC). This study investigated the role of miR-224 expression in MTC and correlated it with mutation status in sporadic MTCs. A consecutive series of 134 MTCs were considered. Patients had a sporadic form in 80% of cases (107/134). In this group, REarranged during transfection (RET) and rat sarcoma (RAS) mutation status were assessed by direct sequencing in the tumor tissues. Quantitative real-time polymerase chain reaction was used to quantify mature hsa-miR-224 in tumor tissue...
2017: International Journal of Endocrinology
https://www.readbyqxmd.com/read/28662997/next-generation-immunohistochemistry-emerging-substitutes-to-genetic-testing
#8
REVIEW
Juliana Andrici, Anthony J Gill, Jason L Hornick
The identification of at-risk kindreds facilitates screening and risk reduction strategies for patients with hereditary cancer predisposition syndromes. Recently, immunohistochemistry (IHC) has emerged as a cost-effective strategy for detecting or inferring the presence of mutations in both tumors and the germline of patients presenting with tumors associated with hereditary cancer predisposition syndromes. In this review we discuss the use of novel IHC markers, including PRKAR1A, β-catenin, SDHB, fumarate hydratase and 2SC, HRASQ61R, BAP1, parafibromin and glucagon, which have either established applications or show promise for surgical pathologists to complement morphological or clinical suspicion of hereditary cancer predisposition syndromes...
June 27, 2017: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/28658345/medullary-thyroid-carcinoma-adverse-events-during-systemic-treatment-risk-benefit-ratio
#9
Léa Maria Zanini Maciel, Patrícia Künzle Ribeiro Magalhães
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from parafollicular C cells of the thyroid and associated with mutations in the proto-oncogene REarranged during Transfection (RET). The prognosis of MTC depends on clinical stage, with a 95.6% 10-year survival rate among patients with localized disease and 40% among patients with advanced disease. Standard chemotherapy and radiotherapy have no significant impact on the overall survival of these patients and two tyrosine kinase receptor inhibitors (TKIs), vandetanib and cabozantinib, have been recently approved for the systemic treatment of locally advanced or metastatic MTC...
June 26, 2017: Archives of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28649091/the-penetrance-of-men2-pheochromocytoma-is-not-only-determined-by-ret-mutations
#10
Frederic Castinetti, Ana Luiza Maia, Mariola Peczkowska, Marta Barontini, Kornelia Hasse-Lazar, Thera P Links, Rodrigo Almeida Toledo, Sarka Dvorakova, Caterina Mian, Maria Joao Bugalho, Stefania Zovato, Maria Alevizaki, Andrei Kvachenyuk, Birke Bausch, Paola Loli, Simona Raluca Bergmann, Attila Patocs, Marija Pfeifer, Fina Biarnes, Ernst von Dobschuetz, Claudio Letizia, Gerlof D Valk, Marcin Barczynski, Malgorzata Czetwertynska, John Tm Plukker, Paola Sartorato, Tomas Zelinka, Petr Vlcek, Svetlana Yaremchuk, Georges Weryha, Letizia Canu, Nelson Wohllk, Frederic Sebag, Martin K Walz, Charis Eng, Hartmut P H Neumann
Multiple endocrine neoplasia type 2A (MEN2A) is a rare syndrome which main component is medullary thyroid carcinoma (MTC). The natural history of MTC is mainly determined by RET mutations. The second main component of MEN2A is pheochromocytoma. The latest American Thyroid Association guidelines suggested ages to begin biological screening for pheochromocytoma depending on RET mutations. However, other factors could modify the natural history of pheochromocytoma. We collected data from a large international cohort, based on 812 patients, and grouped them according to 4 geographical areas: South America, Southern Europe, Central Europe and Western Europe...
June 25, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28647780/analysis-of-newly-identified-and-rare-synonymous-genetic-variants-in-the-ret-gene-in-patients-with-medullary-thyroid-carcinoma-in-polish-population
#11
Maria Sromek, Małgorzata Czetwertyńska, Magdalena Tarasińska, Aneta Janiec-Jankowska, Renata Zub, Maria Ćwikła, Dorota Nowakowska, Magdalena Chechlińska
Gain-of-function germline mutations of the RET proto-oncogene are responsible for initiation of carcinogenesis within the thyroid gland and development of hereditary form of medullary thyroid carcinoma and MEN2 syndrome. Genotype-phenotype correlations are established for most RET mutations, but the importance of the synonymous changes in this gene remains debatable. We aimed to analyze RET gene variants in Polish population. Genetic testing for the RET gene variants was performed with standard methods in 585 people aged 1-85, including 448 patients with medullary thyroid carcinoma and 131 of their first- and second-degree relatives, as well as six patients suspected of MTC/MEN2...
June 24, 2017: Endocrine Pathology
https://www.readbyqxmd.com/read/28646462/diagnostic-utility-of-pet-ct-with-18-f-dopa-and-18-f-fdg-in-persistent-or-recurrent-medullary-thyroid-carcinoma-the-importance-of-calcitonin-and-carcinoembryonic-antigen-cutoff
#12
Ana Reyes Romero-Lluch, Juan Ignacio Cuenca-Cuenca, Raquel Guerrero-Vázquez, Antonio Jesús Martínez-Ortega, Juan Luis Tirado-Hospital, Isabel Borrego-Dorado, Elena Navarro-González
PURPOSE: This study sought to evaluate and compare the utility of 18-F-fluorodihydroxyphenylalanine ((18)F-DOPA) and 18-F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) for identification of lesions in patients with recurrent medullary thyroid carcinoma (MTC). In addition, we analyzed the correlation between the calcitonin (Ct), carcinoembryonic antigen (CEA) levels, each doubling time (DT), and PET positivity. We evaluated the reliability of the 150 pg/mL Ct cutoff set by the American Thyroid Association guidelines for further imaging (including (18)F-DOPA PET/CT)...
June 23, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28644684/c-cell-and-follicular-epithelial-cell-precursor-lesions-of-the-thyroid
#13
Theresa Scognamiglio
CONTEXT: - The identification of precursor or dysplastic lesions in the thyroid is difficult. Pathology of the C cell has been extensively studied, and the preneoplastic nature of C-cell hyperplasia in the setting of familial medullary thyroid carcinomas is well established. However, the distinction between neoplastic and physiologic/reactive C-cell hyperplasia remains a challenge. Unlike C cells, the existence of a precursor lesion of follicular cell-derived tumors is less well established, and a dysplastic or preneoplastic follicular lesion has not been well defined...
June 23, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28643384/cytological-features-of-medullary-thyroid-carcinoma-in-ascitic-effusion
#14
Marilin Rosa
No abstract text is available yet for this article.
June 23, 2017: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/28639924/cushing-syndrome-diagnostic-workup-and-imaging-features-with-clinical-and-pathologic-correlation
#15
Nicolaus A Wagner-Bartak, Ali Baiomy, Mouhammed Amir Habra, Shalini V Mukhi, Ajaykumar C Morani, Brinda R Korivi, Steven G Waguespack, Khaled M Elsayes
OBJECTIVE: Cushing syndrome (CS) is a constellation of clinical signs and symptoms resulting from chronic exposure to excess cortisol, either exogenous or endogenous. Exogenous CS is most commonly caused by administration of glucocorticoids. Endogenous CS is subdivided into two types: adrenocorticotropic hormone (ACTH) dependent and ACTH independent. CONCLUSION: Cushing disease, which is caused by a pituitary adenoma, is the most common cause of ACTH-dependent CS for which pituitary MRI can be diagnostic, with bilateral inferior petrosal sinus sampling useful in equivocal cases...
July 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28639308/discovery-of-novel-wtret-and-v804mret-inhibitors-from-hit-to-lead
#16
Luca Mologni, Martina Dalla Via, Adriana Chilin, Manlio Palumbo, Giovanni Marzaro
Oncogenic activation of the RET kinase has been found in several neoplastic diseases, like medullary thyroid carcinoma, multiple endocrine neoplasia, papillary thyroid carcinoma and non-small cells lung cancer. Currently approved RET inhibitors were not originally designed to be RET inhibitors and their potency against RET kinase has not been optimized. Hence, novel compounds able to inhibit both wtRET and its mutants (e.g. V804MRET) are needed. Herein we present the development and the preliminary evaluation of a new sub-micromolar wtRET/V804MRET inhibitor (69) endowed with 4-anilinopyridine structure, starting from our previously identified 4-anilinopyrimidine hit compound...
June 22, 2017: ChemMedChem
https://www.readbyqxmd.com/read/28638977/spect-ct-and-pet-ct-molecular-imaging-in-medullary-thyroid-carcinoma-are-we-running-in-the-right-direction
#17
EDITORIAL
Anna Margherita Maffione, Francesco Giammarile, Domenico Rubello
No abstract text is available yet for this article.
June 22, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28635560/sorafenib-in-japanese-patients-with-locally-advanced-or-metastatic-medullary-thyroid-carcinoma-and-anaplastic-thyroid-carcinoma
#18
Yasuhiro Ito, Naoyoshi Onoda, Ken-Ichi Ito, Iwao Sugitani, Shunji Takahashi, Iku Yamaguchi, Koki Kabu, Katsuya Tsukada
BACKGROUND: Therapeutic options for treating advanced or metastatic medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) are still limited in Japan even though vandetanib for MTC, and lenvatinib for MTC and ATC have been approved. Sorafenib is an oral multikinase inhibitor approved for the treatment of patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC). We conducted an uncontrolled, open-label, multicenter, single-arm, phase 2 clinical study to evaluate the safety and efficacy of sorafenib in Japanese patients with MTC and ATC...
June 21, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28635211/-problems-and-countermeasures-in-the-treatment-of-medullary-thyroid-carcinoma
#19
X H Chen, Z G Huang
No abstract text is available yet for this article.
June 7, 2017: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke za Zhi, Chinese Journal of Otorhinolaryngology Head and Neck Surgery
https://www.readbyqxmd.com/read/28633552/cabozantinib-for-the-treatment-of-kidney-cancer
#20
REVIEW
Ahmed Abdelaziz, Ulka Vaishampayan
Cabozantinib is a small molecule tyrosine kinase inhibitor that initially showed activity in medullary thyroid cancer and was recently approved by the Food and Drug Administration for the treatment of metastatic renal cell carcinoma after progression on first line therapy. Areas covered: In the METEOR trial, cabozantinib demonstrated significantly improved efficacy in all three endpoints; response rates, progression free survival and overall survival in a randomized trial with everolimus as an active comparator...
July 2017: Expert Review of Anticancer Therapy
keyword
keyword
13756
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"